VR Platform Cyber Integrates with Rarible Protocol, Enabling Users to Sell NFTs in Metaverse
Cyber, a virtual reality (VR) platform that enables artists and collectors to showcase NFTs in fully immersive experiences for free, announced that users can sell NFTs directly on Cyber 3D spaces in the metaverse. This exciting evolution is made possible through the platform’s integration with the Rarible Protocol, the leading open-source and cross-chain NFT protocol designed to drastically simplify the go-to-market process for NFT projects.
With NFTs playing a foundational role in the digital world, Cyber’s new functionality enables collectors and consumers to enjoy a holistic NFT experience within the platform’s unique VR spaces. While it is common for users to buy collectibles via marketplaces online, this immersive experience is one of the first instances where users do not have to exit the simulated world to complete their purchase.
Recommended AI News: Deepdub Raises $20 Million in Series a Funding Led by Insight Partners to Bring AI-Based Dubbing Global
Notably, Cyber’s official integration into the Rarible Protocol enables users to access collectibles beyond the Cyber marketplace itself, and instead include all of the diverse projects existing on the protocol. These include top marketplaces Rarible.com (a separate entity from the Rarible Protocol) and OpenSea, creating an increasingly streamlined experience for users looking to expand their NFT collections.
Crafted to eliminate the need to build an entire NFT storefront or marketplace from scratch, the Rarible Protocol provides the necessary backend technology for decentralized projects. This novel solution enables creators and developers to focus on project customization and tap into an interoperable ecosystem of projects to drive innovation as the market evolves.
Cyber’s new functionality is currently only available for NFTs minted on the Ethereum blockchain through the Rarible Protocol.
Recommended AI News: CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.